Letermovir for R+ Study

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT07706166
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Kidney Transplant
  • Liver Transplant

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Letermovir — DRUG
    1 tablet by mouth, once daily, for 84 days

Study Details

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV. Participants will take letermovir for 84 days.

Key Dates

First listed
Jul 15, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2029
Completion
Aug 31, 2029

Study Design

Enrollment
146 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Receive letermovir
    Participants will take letermovir

Primary Outcome Measure

Efficacy of letermovir as a prophylaxis of CMV [ Time Frame: 84 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Wisconsin - MadisonMadisonWisconsin53792-

Find similar trials in Madison, WI

By research site
University of Wisconsin - Madison· Madison, WI

Related Studies